Abstract
Neuroblastoma has varying presentations and a survival rate that ranges from 0% to 100% depending on the tumor biology. The challenge in managing this tumor is determining which therapies can effectively yet safely produce cure. For patients with high-risk disease, aggressive and novel treatments are needed. For patients with low- and intermediate-risk disease, we continue to define, through prognostic indicators, minimal, least-toxic curative therapies. This chapter describes the recommendations of the Division of Pediatrics at M. D. Anderson Cancer Center for evaluating and treating children and adolescents with neuroblastoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Ater JL, Gardner KL, Foxhall LE, Therrell BL, Bleyer WA. Neuroblastoma screening in the United States: results of the Texas Outreach Program for neuroblastoma screening. Cancer 1998;82:1593–1602.
Berthold F. Overview. Biology of neuroblastoma. In: Carl Pochedly, ed. Neuroblastoma Tumor Biology and Therapy. Boca Raton, FL: CRC Press Inc; 1990.
Chan KW, Petropoulos D, Choroszy M, et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant 1997;20:1039–1043.
Chan LL, Ater J, Cangir A, et al. Fractionated high dose cyclophosphamide for advanced pediatric solid tumors. J Pediatr Hematol Oncol 1996;18:63–67.
De Roos AJ, Olshan AF, Teschke K, et al. Parental occupational exposures to chemicals and incidence of neuroblastoma in offspring. Am J Epidemiol 2001;154:106–114.
Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264–2279.
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165–1173.
Murray JL, Cunningham JE, Brewer H, et al. A phase I trial of murine monoclonal antibody 14G2A (Anti-GD2) given by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184–193.
Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group Study. J Clin Oncol 2000;18:477–486.
Perez CA, Matthay KK, Atkinson JB, et al. Biological variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children’s Cancer Group Study. J Clin Oncol 2000;18:18–26.
Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies—a report from the Children’s Cancer Group Study. Med Pediatr Oncol 2001;36:612–622.
Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children’s Cancer Group study. J Clin Oncol 2000;18:1260–1268.
Woods WG. Screening for neuroblastoma: the final chapters. J Pediatr Hematol Oncol 2003;25:3–4.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Ater, J.L., Worth, L.L. (2005). Neuroblastoma. In: Chan, K.W., Raney, R.B. (eds) Pediatric Oncology. M.D. Anderson Cancer Care Series, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-24472-3_6
Download citation
DOI: https://doi.org/10.1007/978-0-387-24472-3_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24470-9
Online ISBN: 978-0-387-24472-3
eBook Packages: MedicineMedicine (R0)